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Background: Exposure to arsenic is linked to increased risk of human cancer.
Results: Arsenic-treated cells have higher levels of EGFR and tyrosine-phosphorylated PCNA and reduced mismatch repair
activity.
Conclusion: The carcinogenic effect of arsenic may be mediated by its ability to promote EGFR-dependent PCNA phosphor-
ylation, thereby inhibiting mismatch repair.
Significance: Arsenic-stimulated posttranslational modification of PCNA represents a novel mechanism of action for non-
genotoxic carcinogens.
Both genotoxic and non-genotoxic chemicals can act as car-
cinogens. However, while genotoxic compounds lead directly to
mutations that promote unregulated cell growth, the mecha-
nism by which non-genotoxic carcinogens lead to cellular trans-
formation is poorly understood. Using a model non-genotoxic
carcinogen, arsenic, we show here that exposure to arsenic
inhibits mismatch repair (MMR) in human cells, possibly
through its ability to stimulate epidermal growth factor receptor
(EGFR)-dependent tyrosine phosphorylation of proliferating
cellular nuclear antigen (PCNA). HeLa cells exposed to exoge-
nous arsenic demonstrate a dose- and time-dependent increase
in the levels of EGFR and tyrosine 211-phosphorylated PCNA.
Cell extracts derived from arsenic-treated HeLa cells are defec-
tive in MMR, and unphosphorylated recombinant PCNA
restores normal MMR activity to these extracts. These results
suggest a model in which arsenic induces expression of EGFR,
which in turn phosphorylates PCNA, and phosphorylated
PCNA then inhibits MMR, leading to increased susceptibility to
carcinogenesis. This study suggests a putative novel mechanism
of action for arsenic and other non-genotoxic carcinogens.
Arsenic is a widely distributed non-genotoxic environmental
carcinogen. Exposure to arsenic is associated with increased
risk of various types of human cancer, including bladder, kid-
ney, lung, liver, and skin cancer, most notably in countries
where arsenic in drinking water is not tightly regulated (1– 8).
In the United States, although the concentration of arsenic in
drinking water is closely monitored and regulated by the US
Environment Protection Agency, one specific concern is the
fact that arsenic exposure and tobacco use synergistically
increase the risk of lung cancer (9, 10). However, the molecular
basis by which exposure to arsenic increases susceptibility to
cancer is not fully understood.
Although arsenic does not directly interact with DNA
(reviewed in Ref. 11), it may generate reactive oxygen species
(12–16) and inhibit DNA repair (17, 18). A subset of lung can-
cers, especially small cell lung cancers, display microsatellite
instability (MSI)3 (19 –22), the hallmark of DNA mismatch
repair (MMR) deficiency (23, 24). Here, we explore the hypoth-
esis that arsenic contributes to risk of lung cancer by stimulat-
ing protein post-translational modifications that reduce the
efficiency of MMR. This would be consistent with previous
studies showing that tyrosine-phosphorylated PCNA inhibits
MMR in human cells (25–27).
MMR is a critical genome-maintenance system that corrects
potentially mutagenic DNA mispairs that arise during normal
DNA replication and DNA repair synthesis (23, 24). MMR in
human cells involves three stages: initiation, excision and
resynthesis. The initiation stage involves mismatch recognition
by MutS (MSH2-MSH6) or MutS (MSH2-MSH3), followed
by assembly of an MMR initiation complex, which includes
MutS (or MutS), MutL and proliferating cell nuclear anti-
gen (PCNA), and localization of the strand discrimination sig-
nal (a single strand nick) by this complex. The latter part of this
process is incompletely understood. In the second stage of
MMR, exonuclease 1 (Exo1) removes nascent DNA exonucleo-
lytically from a nick distal to the mismatch, generating a single-
strand DNA gap of variable length, in a reaction that requires
MutS (or MutS), MutL, PCNA, and replication protein A
(RPA). During the “resynthesis” phase of MMR, DNA polymer-
ase  fills in the single-strand DNA gap in a reaction that
requires RFC, PCNA, and RPA; finally, DNA ligase I seals the
* This work was supported in part by grants from the National Cancer Insti-
tute (CA167181), National Institutes of Health, of the United States, the
National Natural Science Foundation of China (31370766, 31461143005,
and 30740420548), and Kentucky Lung Cancer Research program.
1 Supported by a National Cancer Institute training grant (T32 CA165990).
2 Holds the Madeline F. James & Edith D. Gardner Chair in Cancer Research. To
whom correspondence should be addressed: Dept. of Toxicology and Can-
cer Biology, University of Kentucky College of Medicine, 789 South Lime-
stone St., Lexington, KY 40536. Tel.: 859-257-7053; Fax: 859-323-1059;
E-mail: gmli@uky.edu.
3 The abbreviations used are: MSI, microsatellite instability; MMR, mismatch
repair; PCNA, proliferating cellular nuclear antigen; RPA, replication pro-
tein A; EGFR, epidermal growth factor receptor.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 290, NO. 23, pp. 14536 –14541, June 5, 2015
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
14536 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290 • NUMBER 23 • JUNE 5, 2015
 by guest on N
ovem
ber 23, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ssDNA break restoring the integrity of the dsDNA genome.
Defects in MMR correlate strongly with MSI and with suscep-
tibility to hereditary non-polyposis colorectal cancer (HNPCC)
and other cancers (23, 24).
This study explores the hypothesis that arsenic inhibits
MMR by stimulating expression of epidermal growth factor
receptor (EGFR) tyrosine kinase, which phosphorylates tyro-
sine 211 (Y211) of PCNA, which in turn inhibits initiation of
MMR in human cells. The results of this study suggest a puta-
tive novel mechanism of action underlying the carcinogenicity
of arsenic.
Experimental Procedures
Cell Culture, Nuclear Extract, and Whole Cell Extract—HeLa
cells were grown in RPMI 1640 medium with 10% fetal bovine
serum. A549 and Beas-2B cells were grown in Dulbecco’s Mod-
ified Eagle Medium with 10% fetal bovine serum in the presence
or absence of virious concentrations (5–15 M) of sodium
meta-arsenite (NaAsO2). All cells were cultured at 37 °C in a
humidified atmosphere of 5% CO2. Unless specified otherwise,
nuclear extracts (NE) were prepared from 2  109 cells as pre-
viously described (28), and whole cell extracts (WCE) were pre-
pared from 6  107 cells. For WCE preparation, cells were col-
lected and treated with washing buffer (20 mM Hepes, pH 7.5, 5
mM KCl, 0.5 mM MgCl2, 0.1% PMSF, 0.5 mM DTT, 1 g/ml
leupeptin, and 0.2 M sucrose). Cells were lysed in the same
buffer without 0.2 M sucrose by passage through a 27-gauge
needle. Proteins were precipitated by addition of ammonium
sulfate to 65% saturation, collected by centrifugation, resus-
pended in lysis buffer, and dialyzed to equilibrium in buffer
containing 20 mM Hepes (pH 7.5), 5 mM KCl, 0.1 mM EDTA,
0.1% PMSF, 0.5 mM DTT, 1 g/ml leupeptin as described
(28).
Western Blot and Immunoprecipitation—Antibodies to
PCNA, EGFR, -tubulin, and -actin were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibody to Y211
phosphorylated PCNA was generated by Bethyl Laboratories,
Inc. (Montgomery, TX). 50 g of whole cell lysate or nuclear
extract was fractionated by SDS-PAGE and the proteins elec-
troblotted to nitrocellulose membrane for 1 h (29). The nitro-
cellulose membrane was blocked with 5% nonfat dry milk
(NFDM) dissolved in TBST (10 mM Tris-HCl (pH 7.5), 0.8%
NaCl, 0.1% (v/v) Tween 20) for 1 h at room temperature.
Then the membrane was incubated overnight at 4 °C with
primary antibody in 5% NFDM. The membrane was washed
three times for 10 min in TBST. The membrane was then
incubated with a secondary antibody (Sigma) at room tem-
perature for 2 h. The membrane was washed three times for
10 min at room temperature in TBST. Proteins were
detected by chemiluminescence (ECL, GE Healthcare) fol-
lowed by autoradiography.
For immunoprecipitation, nuclear extract or whole cell
extract (1 mg) was incubated with 15 l of protein G-agarose
beads (Thermo) for 30 min at 4 °C with shaking. The reaction
was centrifuged at 800  g at 4 °C for 2 min, the supernatant was
incubated overnight with antibody to Y211-phosphorylated
PCNA (5 g). The mixture was incubated with 15 l of pre-
washed protein G-agarose for 2 h at 4 °C with shaking. The
beads were collected and washed three times with LS Buffer
(PBS (pH 7.5), 10% (v/v) glycerol, 0.1% (v/v) Nonidet P-40, and
1 proteinase inhibitor mixture) for 10 min with shaking. The
sample was resuspended in gel loading buffer and heated at
90 °C for 5 min prior to analysis by SDS-PAGE. The gel was
transferred to nitrocellulose membrane and analyzed by West-
ern blot using primary antibody to PCNA.
Heteroduplex Preparation and MMR Assay—DNA sub-
strates used in this study are circular heteroduplex DNA con-
taining a unique G-T mismatch and a strand break 3 to the
mismatch (Fig. 1). The substrate was prepared from M13mp18-
UKY phase series as described previously (30). MMR assays
using nuclear extracts were performed essentially as described
(28, 30). Briefly, 100 ng of heteroduplex DNA was incubated
with 75 g of nuclear extract or whole cell extract at 37 °C for 15
min in a 20-l reaction containing 10 mM Tris-HCl (pH 7.5), 5
mM MgCl2, 1.5 mM ATP, 0.1 mM dNTPs, 1 mM glutathione, and
110 mM KCl. Reactions were terminated by addition of Protein-
ase K. DNA samples were extracted with phenol and recovered
by ethanol precipitation. For reactions with nuclear extract,
DNA was digested with restriction enzymes NsiI (repair-scor-
ing enzyme) and BseRI, and the reaction products were frac-
tionated by 1% agarose gel electrophoresis. For reactions with
whole cell extract (WCE), repair products were digested with
PstI, NsiI (repair-scoring enzyme) and BglI, fractionated by
polyacrylamide gel electrophoresis, and detected by Southern
blot with a 32P-labeled probe. DNA products were visualized by
phosphorimager.
Analysis of MMR Incision/Excision Intermediates—Mis-
match-provoked-excision was evaluated in the same manner as
the MMR assay with 3-nicked heteroduplex DNA, except the
reaction buffer lacked dNTPs. Reaction products were digested
with PstI and BglI, and fractionated by 6% denaturing polyacryl-
amide gel electrophoresis, followed by Southern blot using a
32P-labeled oligonucleotide probe that hybridized near the BglI
site in the nicked strand. Reaction products were detected by
phosphorimager.
Gap-filling DNA Synthesis Assay—DNA resynthesis/gap-fill-
ing was performed using a circular M13mp18 dsDNA contain-
ing a 283-nt ssDNA gap in the same buffer, and reactions con-
ditions as in the MMR assay. Reaction products were digested
with HindIII and BseRI, fractionated through 1% agarose gel
electrophoresis, and detected by UV light after ethidium
bromide.
Protein Expression and Purification—Recombinant human
RPA, PCNA, and GST-p21c were overexpressed in Escherichia
coli BL21 (DE3) from plasmids provided by Marc Wold (Uni-
versity of Iowa), Jerald Hurwitz (Memorial Sloan-Kettering
Cancer Center, New York, NY), and Anindya Dutta (University
of Virginia, Charlottesville, VA), respectively. The recombinant
proteins were purified as described previously (31–34). Recom-
binant human MutS, MutL, and Exo1 were expressed in
insect cells using the Bac-to-Bac expression system (Invitrogen)
as previously described (34 –36). Purified proteins were stored
in liquid nitrogen at 80 °C in 10 to 25-l aliquots in buffer
containing 1 mg/ml bovine serum albumin (BSA).
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Results
Cells Exposed to Arsenic Exhibit Reduced Mismatch Repair
Activity—Nuclear extracts derived from HeLa cells are profi-
cient in MMR in vitro (28, 37). To determine the impact of
arsenic on MMR, whole cell extracts of arsenic-treated or
untreated HeLa cells were prepared and assayed for their ability
to repair a circular DNA heteroduplex containing a G-T mis-
match, using a newly developed MMR assay (Fig. 1A, top panel),
which is more sensitive than the traditional MMR assay (Fig.
1A, bottom). It is worth mentioning that the traditional assay
uses nuclear extract from  2  109 cells (28, 38), but the assay
used here is performed with whole cell extract from 6  107
cells. The results reveal that HeLa cells treated with arsenic are
2-fold less active than untreated HeLa cells (Fig. 1, B and C),
which is consistent with the hypothesis that arsenic directly or
indirectly inhibits MMR.
Arsenic-induced Inhibition of MMR Is Rescued by Exogenous
PCNA—To identify which MMR component is sensitive to
arsenic, purified key MMR components MutS, MutL, and
PCNA were added in excess to both the traditional MMR assay
(Fig. 2A) and the new MMR assay (Fig. 2B) containing extracts
derived from arsenic-treated HeLa cells. The results show that
exogenous PCNA stimulated MMR activity in treated HeLa cell
extracts (Fig. 2A, lane 5; B, lane 5), but not in untreated HeLa
extracts (Fig. 2A, lanes 6 and 7); addition of other MMR com-
ponents did not restore MMR in this experimental system (Fig.
2A, lanes 3 and 4; B, lanes 3 and 4). These results suggest that
arsenic could inhibit MMR through a mechanism involving
functional alteration of PCNA.
Exposure to Arsenic Blocks Mismatch-provoked Incision/
Excision—PCNA is essential for mismatch-provoked incision/ex-
cision, especially in 3 nick-directed MMR (30, 39). The incision/
excision products can be visualized on a Southern blot, by carrying
out the MMR reaction in the absence of deoxyribonucleotide
triphosphates (dNTPs), which blocks DNA resynthesis (30, 40).
This approach was used to examine whether arsenic inhibits mis-
match-provoked incision/excision in HeLa cell extracts, and
whether such inhibition involves PCNA.
As shown in Fig. 2C, extracts derived from untreated HeLa
cells generated expected incision/excision products (lane 1,
DNA bands within bracket). Arsenic treatment greatly reduced
the production of the incision/excision intermediates (Fig. 2C,
lane 2), however, addition of purified recombinant PCNA to
the reaction nearly restored the incision/excision products to
the normal level (compare lane 3 with lane 1). These results
suggest that arsenic inhibits MMR at the initiation stage, and
that this inhibition can be rescued by exogenous PCNA. Thus,
we postulate that endogenous PCNA in arsenic-treated cells
plays a role in inhibiting mismatch-provoked incision/excision.
Effect of Arsenic on Phosphorylation Status of PCNA—Previ-
ous studies suggest that exposure to arsenic stimulates expres-
sion of epidermal growth factor receptor (EGFR) in human
cells, potentially activating EGFR and its downstream targets
and increasing risk of lung cancer (41). Data also show that the
activated EGFR tyrosine kinase phosphorylates PCNA at tyro-
sine 211 (Y211) (42), and that Y211-phophorylated PCNA
(PCNA-p) inhibits initiation of MMR in vitro (25). Therefore, it
is reasonable to propose that arsenic-dependent carcinogenesis
is at least in part mediated by EGFR-phosphorylated PCNA. To
test this hypothesis, EGFR expression, PCNA phosphorylation
status, and MMR capacity were evaluated in arsenic-treated
and control HeLa cells. The results show a time- and dose-de-
FIGURE 1. Reduced MMR activity in arsenic-treated HeLa cells. A, DNA
substrate and MMR assay principles. MMR activity of arsenic-treated and con-
trol HeLa cells was determined by incubating cell extracts with a circular DNA
heteroduplex containing a G-T mismatch and a strand break 172-bp 3 to the
mismatch as described previously (30). Several restriction enzymes used for
scoring incision/excision or repair are shown. Assay I (top panel) shows a
newly developed MMR assay, which employs whole cell extract (WCE) and
Southern blot analysis. The red bar represents 32P-labeled oligonucleotide
probe complementary to the nicked strand at the indicated location. Assay II
(bottom panel) shows the traditional MMR assay, which utilizes nuclear
extract as previously described (28). B, MMR assay showing reduced MMR
activity in WCE of arsenic-treated HeLa cells. C, MMR assay showing reduced
MMR activity in nuclear extract of arsenic-treated HeLa cells.
FIGURE 2. PCNA restores MMR to arsenic-treated HeLa cells. A and B, in
vitro MMR assays showing that nuclear extracts (A) or whole cell extracts (B) of
arsenic-treated HeLa cells exhibit reduced MMR activity, but addition of exog-
enous PCNA, not other key MMR proteins, stimulates in vitro MMR. B, South-
ern blot analysis of mismatch-provoked incision/excision in extracts of arse-
nic-treated and control HeLa cells. The red bar represents 32P-labeled
oligonucleotide probe that anneals to the nicked DNA strand near the BglI
site, and blue bracket includes incision/excision intermediates allowing mis-
match removal by a 5-3 exonuclease such as exonuclease 1.
Arsenic Inhibits DNA Mismatch Repair
14538 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290 • NUMBER 23 • JUNE 5, 2015
 by guest on N
ovem
ber 23, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
pendent correlation between arsenic exposure and expression
of EGFR in HeLa cells (Fig. 3, A and B). PCNA phosphorylation
was quantified in immunoprecipitates associated with a phos-
phorylation-specific antibody to Y211-PCNA, followed by
Western analysis (Fig. 3C). The results reveal that increased
levels of PCNA-p correlate with increased levels of EGFR in
arsenic-treated HeLa cells (Fig. 3, B, C, and D). To determine
that arsenic-mediated MMR inhibition is indeed related to the
EGFR tyrosine kinase activity, HeLa cells were treated with
arsenic in the presence or absence of an EGFR tyrosine kinase
inhibitor, AG-1478, and WCEs derived from these cells were
analyzed for MMR activity using the newly developed MMR
assay (Fig. 1A, top panel). As shown in Fig. 3E, although
AG-1478 slightly inhibits MMR activity (compare lane 5 with
lane 3), it blocks arsenic-mediated inhibitory effect on MMR
(compare lane 5 with lane 8). These data support the notion
that arsenic stimulates expression/activation of EGFR, which in
turn phosphorylates PCNA, leading to inhibition of MMR.
To test the idea that the effect of arsenic on PCNA and MMR
increases susceptibility to lung carcinogenesis, we treated nor-
mal human lung bronchial cells, Beas-2B, and human non-
small lung cancer cells, A549, with arsenic (10 M) for 24 h, and
analyzed EGFR expression, PCNA phosphorylation and MMR
activity. As shown in Fig. 4A, exposure to arsenic led to
increased expression and activation of EGFR (increased abun-
dance of phosphotyrosine proteins) in Beas-2B and A459 cells
as well as to increased levels of PCNA-p (Fig. 4A). Whole cell
extracts derived from arsenic-treated and untreated A549 and
Beas-2B cells were examined for MMR activity (Fig. 1A, top
panel). As shown in Fig. 4B, MMR capacity is lower in extracts
from arsenic-treated A549 and Beas-2B cells than those from
untreated control cells (Fig. 4B, lanes 1 and 2, 4 and 5, respec-
tively). Addition of 5 M of non-phosphorylated recombinant
PCNA completely restored MMR activity in extracts from arse-
nic-treated Beas-2B, but only partially restored MMR activity in
A549 cells. This might indicate a higher level of PCNA-p in
A549 cells than in Beas-2B cells. Indeed, MMR activity was fully
restored when more exogenous PCNA was added to WCE of
arsenic-treated A549 cells (Fig. 4C, lane 5). In summary, these
data are consistent with the hypothesis that arsenic stimulates
EGFR-dependent phosphorylation of PCNA.
Arsenic Exposure Delays Mismatch-provoked DNA Resynthesis—
PCNA is an essential cofactor for efficient DNA resynthesis during
MMR (43). Therefore, the efficiency of DNA resynthesis in
nuclear extracts from arsenic-treated and control cells was
examined using a DNA gap-filling assay (see Fig. 5A). After the
DNA resynthesis reaction, reaction products were cleaved by
restriction enzymes HindIII and BseRI, which cleave ssDNA
(gapped DNA substrate) with very low efficiency. In reactions
carried out for 20 min at 37 °C, the efficiency of DNA resynthe-
sis appeared similar in extracts from arsenic-treated HeLa cells
and control cells in the presence or absence of exogenous
PCNA (Fig. 5B). However, when reactions were carried out for
1, 3, 5, or 10 min, the efficiency of DNA resynthesis was slightly
lower in reactions containing extracts from arsenic-treated
HeLa cells (Fig. 5C, lanes 6 –9) than in NE from control cells
(Fig. 5C, lanes 2–5). This effect was reversed by addition of
exogenous PCNA (Fig. 5C, lanes 10 –13), consistent with the
hypothesis that the effect of arsenic on MMR is mediated by
endogenous PCNA.
FIGURE 3. Arsenic stimulates EGFR expression and PCNA phosphoryla-
tion. A, Western blot quantification of EGFR in HeLa cells treated with 15 M
arsenic for the indicated times. B, Western blot of EGFR in HeLa cells treated
with the indicated concentrations of arsenic for 24 h. C, immunoprecipitation
followed by Western blot of Y211-phosphorylated PCNA (PCNA-p) in HeLa
cells treated with arsenic at the indicated concentration for 24 h. Cell extracts
(1 mg) were immunoprecipitated using a PCNA-Y211 phosphoryla-
tion-specific antibody, and probed using antibody to PCNA. Relative protein
levels were determined using the levels of EGFR (A and B) or PCNA-p (C) in
untreated cells as a reference. D, correlation between EGFR expression and
PCNA phosphorylation. Error bars represent S.D., which were determined
from variations in three independent experiments. E, in vitro MMR activity in
arsenic-treated or untreated HeLa cells in the presence or absence of 10 M
AG-1478.
FIGURE 4. Correlation between EGFR expression, PCNA phosphorylation,
and MMR activity in normal human lung and human lung cancer cells. A,
lung cancer cell line A549 and normal lung cell line Beas-2B were treated with
10 M arsenic for 24 h, cell extracts prepared and analyzed by Western blot
with antibody to EGFR or PCNA-p by IP-Western, as described in Fig. 3. B and
C, MMR activity in arsenic-treated A549 and Beas-2B cells with or without
exogenous PCNA.
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Discussion
Genotoxic carcinogens or their metabolic products directly
or indirectly damage nucleic acids including genomic DNA. In
contrast, the mechanism of many non-genotoxic carcinogens,
while poorly understood, is likely to involve an impact on signal
transduction pathways that regulate or mitigate genetic insta-
bility and/or cell growth. The carcinogenicity of arsenic in
humans is incompletely understood, but it may include geno-
toxic effects mediated by ROS-induced DNA damage (44) or a
non-genotoxic mechanism mediated by induction of EGFR
expression/activity (41) or both.
We show here that arsenic produces similar effects in HeLa,
A549, and BEAS-2B cells, including: 1) inhibition of MMR by a
mechanism mediated by endogenous PCNA (Figs. 1, 2, and 4);
2) induction of EGFR expression/activity (Fig. 3); and 3)
increased abundance of Y211-phosphorylated PCNA. These
data support a model in which arsenic induces EGFR expres-
sion and/or activates the EGFR tyrosine kinase, which in turn
phosphorylates PCNA at Y211, stimulating cell proliferation
(42) while inhibiting MMR and indirectly increasing suscepti-
bility to carcinogenesis. Our recent studies show that Y211-
phosphorylated PCNA promotes misincorporation during
DNA synthesis (25), which could undermine mechanisms that
preserve replication fidelity while promoting mechanisms that
lead to genome instability and cellular transformation (23,
45– 47).
It is well accepted that cancer expresses a mutator phenotype
(48). Based on this theory, acquisition of a large number of
mutations in genes regulating cell growth is a prerequisite for
tumorigenesis. Environmental carcinogens, particularly the
genotoxic carcinogens, can directly or indirectly modify DNA
to form carcinogen-DNA adducts, thereby inducing gene
mutations. However, a cell possesses an array of DNA damage
response and repair pathways to efficiently remove all types of
DNA lesions, including those caused by environmental carcin-
ogens (49, 50). Because of quality and fidelity controls by these
DNA repair systems, it is not easy for a carcinogen-DNA adduct
to be converted into a mutation. In other words, mutations may
only occur when a genome maintenance systems is not func-
tional. How can environmental carcinogens impair DNA repair
systems to induce mutations? The results presented here pro-
vide a clue for the long-standing question: arsenic inhibits
MMR by inducing expression/activation of EGFR, which phos-
phorylates PCNA, a critical component of MMR as well as DNA
replication and DNA repair.
Here, we postulate that post-translational modification of
PCNA impairs MMR in human cells (25), leading to genome
instability and cancer susceptibility. However, many questions
about arsenic-induced carcinogenesis are still not resolved, and
additional studies are needed. Critical unresolved questions
include the mechanism by which arsenic stimulates expression/
activation of EGFR and the translocation of EGFR into the
nucleus, which is presumably a prerequisite to EGFR-depen-
dent phosphorylation of PCNA. It is also not yet understood
how or why tyrosine-phosphorylation of PCNA reduces the
efficiency of MMR.
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